BioVersys AG

BioVersys AG, in Basel, CHE-114.512.761, Aktiengesellschaft (SHAB Nr. 54 vom 19.03.2025, Publ. 1006286040).

Statutenänderung:
27.06.2025. Die Gesellschaft hat mit Beschluss vom 27.06.2025 eine Erhöhung des bedingten Kapitals gemäss näherer Umschreibung in den Statuten beschlossen. Änderung des Kapitalbands gemäss näherer Umschreibung in den Statuten.

Ausgeschiedene Personen und erloschene Unterschriften:
Ropponen, Henni-Karoliina, finnische Staatsangehörige, in Röschenz, Mitglied des Verwaltungsrates, mit Kollektivunterschrift zu zweien.

Eingetragene Personen neu oder mutierend:
Schulze, Ulrik, von Zumikon, in Zumikon, Mitglied des Verwaltungsrates, ohne Zeichnungsberechtigung.

"Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 03.06.2025/nPublicly viewable until: 03.06.2026/nPublication number: UP04-0000007270/nPublishing entity/nHomburger AG, Hardstrasse 201.

8005 Zürich/nInvitation to the ordinary general meeting/nBioVersys AG/nOrganisation concerned:
/nBioVersys AG/nCHE-114.512.761/nHochbergerstr. 60C/n4057 Basel/nGeneral meeting details:/n27.06.2025, 12.00 Uhr.

ZIP Auditorium Stückipark/nHochbergerstrasse 60F/n4057 Basel/nInvitation/Agenda:
/nInvitation to the Annual General Meeting of BioVersys AG. The full text of the invitation is/nincluded in the attached PDF./n1/11/nInvitation/nto the Annual General Meeting of BioVersys AG/nDay: Friday, June 27.

2025/nTime:
12 pm CEST (doors open 11.30 am CEST)/nPlace: ZIP Auditorium Stückipark, Hochbergerstrasse 60F, 4057 Basel/n2/11/nAgenda and Proposals of the Board of Directors/n1. Annual Report 2024 (Annual Financial Statements and Consolidated Financial/n Statements 2024;
Auditor's Reports)/n The Board of Directors proposes that the annual financial statements and the consolidated fi-/n nancial statements 2024 be approved and that the Auditors' reports be acknowledged./n Explanation: In accordance with article 698 paragraph 2 items 3 and 4 of the Swiss Code of Ob-/n ligations (CO) and the Articles of Association, the Annual General Meeting is responsible for ap-/n proving the annual financial statements and the consolidated financial statements./n2. Discharge of the Members of the Board of Directors and the Executive Committee from/n Liability/n The Board of Directors recommends that the members of the Board of Directors and the Execu-/n tive Committee be granted discharge for their activities in the financial year 2024./n Explanation: In accordance with article 698 paragraph 2 item 7 CO and the Articles of Associa-/n tion, the Annual General Meeting is responsible for granting discharge to the members of the/n Board of Directors and the Executive Committee./n3. Appropriation of Financial Result 2024/n The Board of Directors proposes that the accumulated loss of the Company in the amount of/n CHF 79,936 thousand be allocated as follows:/n Loss of the financial year 2024 CHF (14,373 thousand)/n Loss carried forward from previous year CHF (65,563 thousand)/n Balance to be carried forward CHF (79,936 thousand)/n Explanation: In accordance with article 698 paragraph 2 item 4 CO and the Articles of Associa-/n tion, the Annual General Meeting is responsible for passing resolutions on the appropriation of/n the balance sheet profit, allocation of reserves and the payment of a dividend./n 3/11/n4. Elections and/or Re-elections/n4.1 Election/Re-election of the Chairman and the Members of the Board of Directors/n Dr. Seng Chin Mah is standing for and has declared acceptance of his re-election as Chairman/n of the Board of Directors for a term of office until the completion of the next Annual General/n Meeting./n The following current members of the Board of Directors, Dr. David Hunstad, Dr. Marc Gitz-/n inger, Ms. Marina von Schönau and Dr. William Jenkins, are also standing and have declared/n acceptance of their re-election as members of the Board of Directors for a term of office until the/n completion of the next Annual General Meeting./n Dr. Henni-Karoliina Ropponen will not stand for re-election as a member of the Board of Directors./n We thank her for her invaluable contributions to the Board of Directors as well as her efforts/n towards the IPO./n The Board of Directors proposes to elect Dr. Ulrik Schulze as a new member of the Board of Di-/n rectors./n The Board of Directors proposes to re-elect the following members of the Board of Directors,/n and to elect the following new candidate as a member of the Board of Directors, individually and/n for a term of office lasting until the completion of the next Annual General Meeting./n Explanation: Pursuant to article 698 paragraph 2 item 2 and paragraph 3 item 1 CO and the Ar-/n ticles of Association, the Annual General Meeting is responsible for the following elections of the/n Chairman and the members of the Board of Directors. The Board of Directors and the Compen-/n sation and Nomination Committee are convinced that the persons proposed for election and re-/n election, respectively, have the necessary qualifications to serve on the Board of Directors of/n BioVersys./n For biographical details on the candidates to be re-elected, please refer to the company's web-/n site (https://www.bioversys.com/about-us/board-of-directors/)./n Dr. Ulrik Schulze is a senior partner & managing director at The Boston Consulting Group (BCG)./n He led BCG's global biopharma sector for many years and held leadership positions in BCG/n Switzerland, including Head of Business Development, People Chair, and Head of the Health/n Care business. Dr. Schulze has more than 30 years of experience in the life science industry/n working with boards, CEOs, and senior executives in Europe, the US, and Asia. His work has/n focused on strategy development, capital markets, M&A, post-merger integration, and organiza-/n tional transformations across the value chain. In 2022, he co-authored the report ""The case for a/n subscription model to tackle antimicrobial resistance"". He is also a co-founder of ReproNovo SA,/n a biotech company in reproductive medicine, that has raised USD 65 million in Series A funding/n and Sanrigen GmbH, a life science advisory firm. Dr. Schulze is Swiss, born in 1967 and holds a/n doctorate degree in Biotechnology from the Technical University of Denmark./n 4/11/n4.1.1 Re-election of Seng Chin Mah as Chairman of the Board of Directors/n4.1.2 Re-election of David Hunstad as Member of the Board of Directors/n4.1.3 Re-election of Marc Gitzinger as Member of the Board of Directors/n4.1.4 Re-election of Marina von Schönau as Member of the Board of Directors/n4.1.5 Re-election of William Jenkins as Member of the Board of Directors/n4.1.6 Election of Ulrik Schulze as Member of the Board of Directors/n4.2 Re-election of the Members of the Compensation and Nomination Committee/n The current members of the Compensation and Nomination Committee, Dr. Seng Chin Mah,/n Dr. David Hunstad and Ms. Marina von Schönau, have declared acceptance of their re-election/n as members of the Compensation and Nomination Committee for a term of office until the com-/n pletion of the next Annual General Meeting, subject to their re-election as Chairman or member/n of the Board of Directors, respectively. The Board of Directors proposes to re-elect the following/n members of the Compensation and Nomination Committee individually and for a term of office/n lasting until the completion of the next Annual General Meeting./n4.2.1 Re-election of Seng Chin Mah as Member of the Compensation and Nomination/n Committee/n4.2.2 Re-election of David Hunstad as Member of the Compensation and Nomination/n Committee/n4.2.3 Re-election of Marina von Schönau as Member of the Compensation and Nomination/n Committee/n Explanation: Pursuant to article 698 paragraph 3 item 2 CO and the Articles of Association, the/n Annual General Meeting is responsible for the election of the members of the Nomination & Re-/n muneration Committee. The Board of Directors and the Nomination & Remuneration Committee/n are convinced that the persons proposed for re-election have the necessary qualifications to/n serve on the Nomination & Remuneration Committee./n 5/11/n4.3 Election of the Independent Voting Rights Representative/n The Board of Directors proposes to elect Lenz Caemmerer, Attorneys at Law & Notaries, Elisa-/n bethenstrasse 15, 4010 Basel as Independent Voting Rights Representative for a term of office/n until the completion of the next Annual General Meetin"

BioVersys AG, in Basel, CHE-114.512.761, Aktiengesellschaft (SHAB Nr. 27 vom 10.02.2025, Publ. 1006252149).

Statutenänderung:
17.03.2025.

Aktienkapital neu:
CHF 5'823'480.00 [bisher: CHF 5'775'618.00].

Liberierung Aktienkapital neu:
CHF 5'823'480.00 [bisher: CHF 5'775'618.00].

Aktien neu:
5'823'480 Namenaktien zu CHF 1.00 [bisher: 5'775'618 Namenaktien zu CHF 1.00]. Ordentliche Kapitalerhöhung innerhalb Kapitalband.